Loews (LTR) AI Stock Analysis

Company Guidance

In the fourth quarter of 2024, Loblaws Incorporated reported strong financial performance, with full-year revenue reaching $61 billion and adjusted earnings surpassing $2.6 billion. The company achieved a 2.9% increase in consolidated revenue for the quarter, totaling $14.9 billion, while adjusted EBITDA grew by 4%. Adjusted diluted net earnings per share rose by 10% to $2.20, although GAAP net earnings decreased by 14.6% due to a $129 million non-cash charge related to the PC Optimum program. Loblaws repurchased $1.8 billion worth of shares and increased its dividend per share by 13.9%. The company also expanded its retail footprint by adding 52 new food and drug retail stores and 78 pharmacy care clinics, representing a 1.1% increase in square footage. Looking ahead, Loblaws plans to invest over $10 billion in the Canadian economy over the next five years, including opening 80 new stores and approximately 100 pharmacist care clinics in 2025. Despite challenges such as inflationary pressures and a declining Canadian dollar, the company anticipates high single-digit growth in adjusted earnings per share for 2025, bolstered by an additional fiscal week and continued investment in its retail and distribution networks.